<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379001</url>
  </required_header>
  <id_info>
    <org_study_id>K23AG031320</org_study_id>
    <nct_id>NCT01379001</nct_id>
  </id_info>
  <brief_title>Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI</brief_title>
  <official_title>Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebrew Rehabilitation Center, Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebrew Rehabilitation Center, Boston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will look at how medications affect the pattern of blood flow in the
      brain. This study will use a special type of MRI (magnetic resonance imaging) scan called
      perfusion MRI to make measurements of cerebral (brain) blood flow. The medications we will
      use in this study are scopolamine (commonly used to treat motion sickness), mecamylamine
      (used to treat high blood pressure), and donepezil (used to treat memory loss). Cognitive
      testing will also be obtained, and correlated with the blood flow patterns in the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Summary: This research project will investigate the value of combined pharmacologic
      manipulation and arterial spin-labeled perfusion MRI (pharmacologic ASL-pMRI) as an in vivo
      probe of cholinergic function. Methods to investigate cholinergic function in vivo are needed
      to better understand the role of acetylcholine in the physiology of the cerebral cortex, and
      in cognitive processes in health and in disease states. In this study, pharmacologic ASL-pMRI
      will be used to characterize the normal cerebral perfusion response to cholinergic
      manipulation in young healthy subjects. Cognitive measures will also be obtained and
      correlated with cerebral perfusion changes. Pharmacologic ASL-pMRI and cognitive testing will
      then be used to study how the cholinergic response is altered with normal aging and in
      delirium
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>3 hours</time_frame>
    <description>cerebral blood flow will be measured 3 hours after drug administration using Arterial spin-labeled perfusion MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive performance</measure>
    <time_frame>4 hours</time_frame>
    <description>participants will undergo cognitive testing following drug administration and MRI acquisition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cholinergic Function</condition>
  <arm_group>
    <arm_group_label>Young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Young healthy controls, aged 21-35</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Older healthy controls, aged 65-80</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)</description>
    <arm_group_label>Young</arm_group_label>
    <arm_group_label>Older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IM or PO placebo</description>
    <arm_group_label>Young</arm_group_label>
    <arm_group_label>Older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>donepezil 5mg PO x 1</description>
    <arm_group_label>Older</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

        Exclusion Criteria:

          -  Any neurological condition, such as brain tumor, history of stroke, seizure disorder,
             attention deficit disorder, normal pressure hydrocephalus, dementia, traumatic brain
             injury

          -  Any major medical conditions, such a cancer, diabetes, glaucoma, prostate disease,
             uncontrolled hypertension

          -  antihistamine use

          -  tricyclic antidepressant use

          -  presence of metal in body, including pacemaker, defibrillator, neurostimulator, metal
             implants, or foreign metal objects such as bullets or shrapnel.

          -  anxiety or panic disorder

          -  history of claustrophobia

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara Fong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebrew Rehabilitation Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebrew Rehabilitation Center, Boston</investigator_affiliation>
    <investigator_full_name>Tamara Fong</investigator_full_name>
    <investigator_title>Assistant Scientist/Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>cholinergic function</keyword>
  <keyword>aging</keyword>
  <keyword>pharmacologic MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Cholinergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

